HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.

AbstractBACKGROUND:
The model for end-stage liver disease (MELD) is used in prioritizing cirrhotic patients awaiting liver transplantation. Patients with small hepatocellular carcinoma (HCC) are eligible candidates. An HCC-MELD equation was recently proposed to predict the dropout rate of HCC patients on the waiting list. This study aimed to validate the accuracy of this equation.
METHODS:
We investigated 390 patients with small HCC who were candidates for liver transplantation and underwent locoregional therapy.
RESULTS:
The estimated probability of dropout according to the equation was 8.2% for T1 stage and 13.5% for T2 stage HCC (p < 0.0001). The actual disease progression rate at three months was 2.1% for T1 and 3.0% for T2 stage HCC. At six months, the progression rate was 5.3% for T1 stage and 6.8% for T2 stage. The area under receiver operating characteristic curve of the HCC-MELD equation was 0.81 at three months and 0.80 at six months. Patients undergoing radiofrequency ablation (RFA) had significantly lower dropout rates compared with other treatment groups according to the equation (p = 0.0007). The actual tumor progression rate was also the lowest for the RFA group at both three and six months.
CONCLUSION:
The HCC-MELD equation is a feasible predictive model for patients with small HCC undergoing locoregional therapy.
AuthorsTeh-Ia Huo, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jen-Huei Chiang, Yi-You Chiou, Samantha C Huo, Pui-Ching Lee, Shou-Dong Lee
JournalClinical transplantation (Clin Transplant) 2008 Jul-Aug Vol. 22 Issue 4 Pg. 469-75 ISSN: 1399-0012 [Electronic] Denmark
PMID18318736 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Topics
  • Adult
  • Aged
  • Carcinoma, Hepatocellular (complications, surgery)
  • Catheter Ablation
  • Chemoembolization, Therapeutic
  • Decision Support Techniques
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Health Care Rationing
  • Humans
  • Liver Neoplasms (complications, surgery)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Models, Biological
  • Neoplasm Staging
  • Patient Dropouts
  • Patient Selection
  • Probability
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: